Ticker Details
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.
IPO Date:	September 7, 2005
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.44B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.43 | 2.12%
Avg Daily Range (30 D):	$4.03 | 1.85%
Avg Daily Range (90 D):	$3.67 | 1.79%

Institutional Daily Volume
Avg Daily Volume:	.31M
Avg Daily Volume (30 D):	.17M
Avg Daily Volume (90 D):	.16M

Trade Size
Avg Trade Size (Sh.):	101
Avg Trade Size (Sh.) (30 D):	28
Avg Trade Size (Sh.) (90 D):	31

Institutional Trades
Total Institutional Trades:	5,612
Avg Institutional Trade:	$3.19M
Avg Institutional Trade (30 D):	$5.18M
Avg Institutional Trade (90 D):	$4.93M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.33M
Avg Closing Trade (30 D):	$5.56M
Avg Closing Trade (90 D):	$5.3M
Avg Closing Volume:	29.78K

News

May 4, 2026 @ 5:25 PM Villere St Denis Liquidates $18 Million Euronet Wo... Source: Eric Trie

Apr 28, 2026 @ 9:40 PM XOMA Investors Have the Opportunity to Join Invest... Source: Schall Law Firm

Apr 27, 2026 @ 5:18 PM Ligand Bets On Royalty Growth With XOMA Buyout Wor... Source: Vandana Singh

Apr 27, 2026 @ 2:58 PM $HAREHOLDER ALERT: The M&A Class Action Firm Annou... Source: Monteverde & Associates Pc

Apr 27, 2026 @ 11:00 AM Ligand to Acquire XOMA Royalty, Further Accelerati... Source: Na

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$7.9	$-.67	$2.33
Diluted EPS	$7.43	$-.67	$2.18
Revenue	$274.48M	$51.72M	$59.67M
Gross Profit
Net Income / Loss	$153.56M	$-13.35M	$44.78M
Operating Income / Loss	$94.59M	$17.37M	$13.84M
Cost of Revenue
Net Cash Flow	$67.03M	$-59.83M	$35.55M
PE Ratio

Splits
Nov 19, 2010	1:6